TAILORx Figure: Perceived Cognitive Impairments (IMAGE)
Caption
A comparison of cognitive function in two groups of TAILORx women with early breast cancer revealed that the group given chemotherapy plus hormone therapy had more significant cognitive impairment at three and six months than the group on hormone therapy alone. However, at 12 and 36 months, the impairment was not significantly different between groups. The similarity was not because the women who had chemotherapy improved, but rather because women on hormone therapy were also reporting cognitive impairment, although the pace of decline was slower and more gradual.
Credit
ECOG-ACRIN Cancer Research Group
Usage Restrictions
None
License
Licensed content